Dexchlorpheniramine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | POLARAMINE | — | 1981-07-14 | fda.gov ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 38 trials | ||||||
| Phase 3 | NCT02735070 | Sep 2016 → Mar 2017 | — | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT02675374 | Jun 2016 → Jul 2017 | — | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 3 | NCT01257061 | Sep 2012 → Apr 2013 | atopic eczema | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01233934 | Feb → Jul 2011 | insect Stings, hypersensitivity to | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01085721 | — | viral respiratory tract infection | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT00995397 | — | insect Stings, hypersensitivity to | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01237925 | — | sunburn | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01085851 | — | sunburn | Mantecorp Industria Quimica e Farmaceutica Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00846950 | Dec 2006 → May 2007 | — | Maastricht University Medical Center | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT02583594 Background | Dec 2015 → Mar 2016 | multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT05136976 Comparator | Jun 2023 → Dec 2027 expected | polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG | University Hospital of Saint-Etienne | Recruiting | No outcome recorded |
| Phase 3 | NCT04702256 Background | Dec 2021 → Dec 2031 expected | lupus nephritis, systemic lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT03368664 Background | Oct 2017 → May 2021 | multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01529242 Comparator | Feb 2014 → Aug 2016 | hypersensitivity reaction disease | EMS | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01529229 Comparator | Nov 2013 → Oct 2014 | allergic rhinitis | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01720485 Comparator | Oct → Dec 2013 | allergic rhinitis | EMS | Unknown | No outcome recorded |
| Phase 4 | NCT02441894 Background | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| — | NCT03805035 Comparator | Jan → Jun 2019 | — | China Medical University Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexchlorpheniramine | “The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine.” NCT02735070 ↗16“Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion” NCT01257061 ↗ |
| Known as | chlorpheniramine | “antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)” NCT03805035 ↗ |
| Known as | DCPA | “histamine H1 receptor antagonist dexchlorpheniramine (DCPA) facilitates EA analgesia in healthy human subjects.” PMID 36081814 ↗ Apr 2022 |
| Known as | Dexchlorpheniramine maleate | “Dexchlorpheniramine maleate 1% cream is a topical anti-histaminic formulation approved by ANVISA in Brazil for the relief of skin irritation and allergies, including the ones...” NCT00995397 ↗6“Dexchlorpheniramine maleate 1% cream is a topical antihistamine formulation approved by ANVISA in Brazil for the relief of skin irritation and pruritus, including the ones...” NCT01085851 ↗ “Dexchlorpheniramine maleate 1% cream is a topical antihistamine formulation approved by ANVISA in Brazil for the relief of skin irritation and pruritus, including the ones...” NCT01237925 ↗ “The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% gel) with the standard preparation (1% cream)” NCT01233934 ↗ “dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution” NCT01529242 ↗ “antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)” NCT03805035 ↗ “IV Dexchlorpheniramine Maleate IV: 10 mg” NCT05136976 ↗ |
| Action | Inhibit | “histamine H1 receptor antagonist dexchlorpheniramine (DCPA)” PMID 36081814 ↗ Apr 2022 |
| Route | Topical | “Small amount applied over the lesion twice a day for 7 days” NCT01085851 ↗ |